Antisense Therapeutics Limited
ATHJF · OTC
6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.06 | -0.05 | 0.29 | -0.86 |
| FCF Yield | -63.75% | -16.30% | -12.19% | -5.77% |
| EV / EBITDA | -0.34 | -3.46 | -7.73 | -11.79 |
| Quality | ||||
| ROIC | -125.64% | -131.80% | -35.62% | -143.89% |
| Gross Margin | 97.91% | 93.97% | 94.98% | 82.12% |
| Cash Conversion Ratio | 0.85 | 0.72 | 1.34 | 0.72 |
| Growth | ||||
| Revenue 3-Year CAGR | 18.63% | 39.84% | 38.55% | -0.52% |
| Free Cash Flow Growth | -23.70% | -4.76% | -33.66% | -47.70% |
| Safety | ||||
| Net Debt / EBITDA | 0.99 | 0.95 | 3.26 | 0.71 |
| Interest Coverage | -3,284.07 | -1,636.62 | -639.17 | -808.95 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.15 | 0.00 |
| Cash Conversion Cycle | -21,590.34 | -3,538.39 | 1,529.11 | -175.06 |